PharmaEngine, Inc. and Guangzhou BeBetter Medicine Technology Signed a Collaboration and Research Agreement
1/3/2013 9:25:24 AM
TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEngine, Inc. (TWO: 4162) announced today the execution of a Collaboration and Research Agreement with Guangzhou BeBetter Medicine Technology Co., Ltd. (BeBetter). The two companies will collaborate to design, synthesize and develop new chemical entities (“drug candidates”) against predefined targets in oncology. This collaboration opens a new chapter for partnership between Taiwan and China in searching for novel anti-cancer drugs. Under the terms of the agreement, PharmaEngine will hold the exclusive worldwide rights of manufacturing, development and commercialization of new drug candidates with the exception of China, while BeBetter will keep the respective rights in China (including Hong Kong and Macau). BeBetter is responsible for discovering optimized compounds for IND-enabling studies. PharmaEngine will be responsible for development and commercialization.